G
14.76
0.56 (3.94%)
| Previous Close | 14.20 |
| Open | 14.39 |
| Volume | 575,073 |
| Avg. Volume (3M) | 843,166 |
| Market Cap | 458,284,736 |
| Price / Sales | 11.56 |
| Price / Book | 0.690 |
| 52 Weeks Range | |
| Earnings Date | 13 Aug 2024 |
| Operating Margin (TTM) | -482.59% |
| Diluted EPS (TTM) | -59.59 |
| Quarterly Revenue Growth (YOY) | 19.10% |
| Total Debt/Equity (MRQ) | 2.67% |
| Current Ratio (MRQ) | 9.70 |
| Operating Cash Flow (TTM) | -464.88 M |
| Levered Free Cash Flow (TTM) | -236.88 M |
| Return on Assets (TTM) | -11.98% |
| Return on Equity (TTM) | -62.22% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bearish | Bearish |
| Diagnostics & Research (Global) | Bearish | Bearish | |
| Stock | GRAIL, Inc. | Bullish | - |
AIStockmoo Score
0.9
| Analyst Consensus | 3.5 |
| Insider Activity | -1.5 |
| Price Volatility | 1.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.90 |
|
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| % Held by Insiders | 14.18% |
| % Held by Institutions | 66.34% |
| 52 Weeks Range | ||
| Median | 43.00 (191.33%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Canaccord Genuity | 14 May 2025 | 43.00 (191.33%) | Buy | 32.89 |
| 21 Apr 2025 | 32.00 (116.80%) | Buy | 26.42 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |